Nonsquamous penile cancers comprise 5% of penile malignancies, though their clinicopathologic features and prognostic significance remain unknown. We used a national cancer registry to detail clinical characteristics and compare cancer-specific mortality (CSM) of nonsquamous cancers with squamous cell carcinoma (SCC).
This study was carried out to assess whether a prolonged time between primary transurethral resection of non-muscle-invasive bladder cancer (TURB) and implementation of bacillus Calmette-Guerin (BCG) immunotherapy (time to BCG; TTBCG) is associated with adverse oncological survival in patients with T1 high-grade (HG) non-muscle-invasive bladder cancer (NMIBC).
bladder cancer is one of the most common urinary tract malignancies. Establishment of robust predictors of disease progression and outcome is important for personalizing treatment of non-muscular invasive bladder carcinoma (NMIBC).
San Francisco, CA (UroToday.com) — The Australian Clinical Trials Alliance (ACTA) has recognised the remarkable Australians who advance the health system through clinical trials at the virtual Clinical Trials 2020: National Tribute and Award Ceremony.
(UroToday.com) During the joint Society of Urologic Oncology / Young Urologic Oncologists Symposium on Clinical Research and Clinical Trials, Dr. Scott Delacroix presented a practical outline for one approach to building involvement in clinical trials as a young investigator in the National Clinical Trials Network (NCTN).
Renal cell carcinoma (RCC) with sarcomatoid features (sRCC) is an aggressive cancer that comprises approximately 5% of all RCC patients, including an estimated 10%-20% of patients with advanced disease.1-3 Although the presence of sarcomatoid features is known to be an independent predictor of poor survival, previous clinical trial data assessing the role of immunotherapy in […]
(UroToday.com) During the joint Society of Urologic Oncology / Young Urologic Oncologists Symposium on Clinical Research and Clinical Trials, Dr. Scott Eggner presented a personal perspective on building a successful career as an academic clinical researcher.
Low rate of cystectomy and delayed time to cystectomy among patients who achieved complete response Patient characteristics or prior treatment history do not influence response Significant anti-adenovirus antibody response does not appear to affect patient outcomes San Francisco, CA (UroToday.com) — FerGene Inc. announced new data analyses results from the landmark Phase 3 clinical trial evaluating […]
Radium-223 dichloride (Ra-223) therapy improves overall survival in bony metastatic castration-resistant prostate cancer (mCRPC) patients. Recent guidance change recommends Ra-223 following at least two prior therapies for mCRPC.
Radioligand therapy is a type of internal radiotherapy combining a short-range radioisotope labeled to a carrier with a high affinity for a specific receptor expressed on tumor cells. Targeted alpha therapy (TAT) combines a high-linear energy transfer (LET) emitter (225Ac) with a prostate-specific membrane antigen (PSMA) carrier, specifically binding tumor cells in patients with metastatic […]
